Oral Glycopyrrolate Liquid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebral Palsy
Conditions
Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea
Trial Timeline
Mar 1, 2007 → Jun 1, 2008
NCT ID
NCT00491894About Oral Glycopyrrolate Liquid
Oral Glycopyrrolate Liquid is a phase 3 stage product being developed by Shionogi for Cerebral Palsy. The current trial status is completed. This product is registered under clinical trial identifier NCT00491894. Target conditions include Cerebral Palsy, Neurological Conditions, Mental Retardation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00491894 | Phase 3 | Completed |
Competing Products
20 competing products in Cerebral Palsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mouse nerve growth factor | Sun Pharmaceutical | Approved | 85 |
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| UDI-001 | Rohto Pharmaceutical | Phase 1/2 | 41 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| NXY-059 | AstraZeneca | Phase 3 | 77 |
| Comparator: Placebo + Comparator: MK0724 | Merck | Phase 2 | 52 |
| Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg | Merck | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| Ponezumab | Pfizer | Phase 2 | 51 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| Azithromycin + Pyrimethamine + Leucovorin calcium | Pfizer | Phase 1 | 32 |
| clopidogrel (SR25990C) | Sanofi | Approved | 84 |
| Intrarectal quinine | Sanofi | Phase 3 | 76 |
| Piracetam | UCB | Approved | 82 |
| Placebo + ALN-APP | Alnylam Pharmaceuticals | Phase 2 | 49 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |